<DOC>
	<DOCNO>NCT01483690</DOCNO>
	<brief_summary>This pilot study use decitabine vorinostat chemotherapy vincristine , dexamethasone , mitoxantrone , peg-asparaginase pediatric patient acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>A Pilot Study Decitabine Vorinostat With Chemotherapy Relapsed ALL</brief_title>
	<detailed_description>Decitabine demethylating agent vorinostat HDAC inhibitor . The use demethylating agent HDAC inhibitor combination previously show synergistic effect alter neoplastic pathway cancer cell well tolerate human clinical study . With ability decitabine vorinostat alter abnormal cellular pathway leukemic blast essentially turn anti-apoptotic protein , leukemia cell become primed cytotoxic cell kill via chemotherapeutic agent . This study ask question whether combination decitabine vorinostat follow chemotherapy feasible whether positively impact outcome patient relapse refractory acute lymphoblastic leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must ≥1 ≤ 21 year age originally diagnose ALL . Diagnosis Patients must diagnosis acute lymphoblastic leukemia ( ALL ) ≥ 25 % blast bone marrow ( M3 ) , without extramedullary disease . Patients may CNS 1 , 2 3 disease . Karnofsky &gt; 50 % patient &gt; 16 year age Lansky &gt; 50 % patient ≤ 16 year age . Prior Therapy Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Patients must 2 prior therapeutic attempt define : Relapse go remission reinduction first subsequent relapse ( ie : 2nd , 3rd , 4th…relapse ) , OR Refractory disease first great relapse reinduction attempt , OR Failing go remission original diagnosis 2 previous induction attempt . Hematopoietic Stem Cell Transplant : Patients experience relapse HSCT eligible , provide evidence GraftversusHost Disease ( GVHD ) least 60 day posttransplant time enrollment . Prior anthracycline exposure : Patients must less 400 mg/m2 lifetime exposure anthracycline chemotherapy . ( See Appendix II calculation worksheet ) Hematopoietic grow factor : It must least 7 day since completion therapy GCSF growth factor time enrollment . It must least 14 day since completion therapy pegfilgrastim ( Neulasta® ) . Biologic ( antineoplastic ) therapy : It must least 7 day last biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair Monoclonal antibody : At least 3 halflives antibody must elapse last dose monoclonal antibody . ( ie . Rituximab=66 day , Epratuzumab=69 day ) Immunotherapy : At least 42 day completion type immunotherapy , e.g . tumor vaccine . Renal Hepatic Function Patient 's serum creatinine must ≤ 1.5 x institutional upper limit normal ( ULN ) accord age . If serum creatinine great 1.5 time normal , patient must calculate creatinine clearance radioisotope GRF ≥ 70mL/min/1.73m2 . Patient 's ALT AST must &lt; 5 x institutional upper limit norm ULN . The hepatic requirement waive patient know suspected liver involvement would otherwise eligible consultation Study Chair Vice Chair . Patient 's total bilirubin must ≤ 1.5 x ULN . The hepatic requirement waive patient know suspected liver involvement would otherwise eligible . Cardiac Function : Patient must shorten fraction ≥ 27 % Echo ejection fraction ≥ 50 % MUGA . Reproductive Function Female patient childbearing potential must negative urine serum pregnancy test confirm prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study . Patients exclude receive Valproic Acid ( VPA ) therapy . Patients exclude know allergy drug use study . Patients exclude systemic fungal , bacterial , viral infection exhibit ongoing signs/symptoms related infection without improvement despite appropriate antibiotic treatment . Patients exclude plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period . Patients exclude significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance protocol treatment procedure , interfere consent , study participation , follow , interpretation study result . Patients exclude positive fungal culture last 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Refractory</keyword>
	<keyword>Acute</keyword>
	<keyword>Childhood</keyword>
	<keyword>Pediatric</keyword>
	<keyword>ALL</keyword>
</DOC>